There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Arcturus Therapeutics (ARCT – Research Report), Gamida Cell (GMDA – Research Report) and Ardelyx (ARDX – Research Report) with bullish sentiments.
Arcturus Therapeutics (ARCT)
Piper Sandler analyst Yasmeen Rahimi maintained a Buy rating on Arcturus Therapeutics today and set a price target of $140.00. The company’s shares closed last Tuesday at $19.40.
According to TipRanks.com, Rahimi is a 2-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Arcturus Therapeutics with a $69.00 average price target, which is a 261.3% upside from current levels. In a report issued on November 5, Wells Fargo also maintained a Buy rating on the stock with a $45.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
Gamida Cell (GMDA)
In a report released today, Edward Tenthoff from Piper Sandler maintained a Buy rating on Gamida Cell, with a price target of $2.00. The company’s shares closed last Tuesday at $0.37, close to its 52-week low of $0.33.
According to TipRanks.com, Tenthoff is a 4-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Gamida Cell with a $4.00 average price target, implying a 614.3% upside from current levels. In a report released yesterday, Needham also maintained a Buy rating on the stock with a $6.00 price target.
Ardelyx (ARDX)
Piper Sandler analyst Christopher Raymond maintained a Buy rating on Ardelyx today and set a price target of $12.00. The company’s shares closed last Tuesday at $3.98.
According to TipRanks.com, Raymond is a 3-star analyst with an average return of
Currently, the analyst consensus on Ardelyx is a Strong Buy with an average price target of $9.92, representing a 153.7% upside. In a report issued on October 31, TD Cowen also maintained a Buy rating on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on ARCT:
- Arcturus Therapeutics (ARCT) Q3 Earnings Cheat Sheet
- Acelyrin appoints Patricia Turney as chief technical operations officer
- Arcturus Therapeutics management to meet with William Blair
- Arcturus Therapeutics partner to receive $165M from Japanese government
- Developers of mRNA Vaccines Honored with Nobel Prize
